Martino, S., Ratanatharathorn, V., Karanes, C. et al. J Cancer Res Clin Oncol (1987) 113: 376. doi:10.1007/BF00397722
We have treated 25 patients, 7 with breast cancer and 18 with non-Hodgkin's lymphoma, with recombinant alpha2 interferon. In 5 patients we observed cardiac arrhythmias that were unexpected and required treatment. No deaths have occured that we can attribute to interferon, though 1 patient had to be resuscitated. Age, prior cardiac disease, prior treatment with doxorubicin, and interferon dose appear to be predisposing factors for this toxicity.